Dr. Carbone Discusses Pain Management

Article

David Carbone, MD, PhD, a survivor of lymphoma and director, James Thoracic Center, The Ohio State University Comprehensive Cancer - The James, discusses pain management in the context of being a patient and a physician.

David Carbone, MD, PhD, a survivor of lymphoma and director, James Thoracic Center, The Ohio State University Comprehensive Cancer — The James, discusses pain management in the context of being a patient and a physician.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
FDA

FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line

December 2nd 2023
Article

The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Lenalidomide/Rituximab Induces Durable Responses in Mantle Cell Lymphoma in 9-Year Follow-Up

Lenalidomide/Rituximab Induces Durable Responses in Mantle Cell Lymphoma in 9-Year Follow-Up

November 27th 2023
Article

The combination of lenalidomide and rituximab led to a median progression-free survival of 9 years—with 17 ongoing responses—among patients with mantle cell lymphoma.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

FDA

FDA Launches Priority Review of Liso-Cel in Pretreated CLL/SLL

November 10th 2023
Article

Lisocabtagene maraleucel is under consideration as a potential treatment option for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Ibrutinib Maintenance Therapy Shows Benefit in MCL Following Induction Therapy

Ibrutinib Maintenance Therapy Shows Benefit in MCL Following Induction Therapy

November 4th 2023
Article

The 3-year progression-free survival rate was 94% and the 3-year overall survival rate was 97%.

© 2023 MJH Life Sciences

All rights reserved.